Press releases

Eevia Health Plc: Flagging notification

Eevia Health Plc ("the Company" or "Eevia") has become aware that one of the Company's shareholders, Futur Pension Holding AB's has an indirect holding via Futur Pension Försäkringsaktiebolag of 672,307 shares in the Company. The holding has decreased from 743,500 shares and the holding now corresponds to approximately 4,82 % of total shares and votes in Eevia.

Seinäjoki, Finland 26.11.2021

For more information, please contact: 
Kim Nurmi-Aro, CFO
kim@eeviahealth.com
Tel.: +358 504 44 0717

About Eevia

Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild-harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.

Eevia Health is a fast-growing Finnish manufacturer of 100% organically certified plant extracts. Although a significant product; Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion. Eevia's branded ingredients, such as Feno-Myrtillus® Organic (high concentrate bilberry extracts with 36% anthocyanins) and Fenoprolic® 70 Organic (pine bark extracts with 70% oligomeric proanthocyanidins), are organically certified. 

Eevia Health operates a modern green-chemistry production facility in Finland. The factory operates near the raw material harvest areas. A uniquely short value chain enables an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name EEVIA.

To learn more, please visit  www.eeviahealth.com or follow Eevia Health on LinkedIn @EeviaHealth. 

2022-05-11
Regulatory

Eevia Health Plc, ("Eevia" or "The Company"), has received a sales order from its Australian distributor Ingredients Plus. Ingredients Plus serves leading nutraceutical brands in Oceania and Asia with high-quality ingredients. The end customer is a major natural health company based out of Sydney, Australia selling its products across Asia and Oceania.

2022-03-15
Regulatory

Eevia Health Plc ("Eevia" or "The Company") is welcoming Gabriella Beni as our new Chief Financial Officer. Kim Nurmi-Aro will leave the Company on March 16th and the Company wishes him the very best in his new professional endeavors close to his home in the city of Vaasa. Gabriella Beni will take over the position on March 17th.

2022-03-09
Regulatory

Eevia Health Plc ("Eevia" or "The Company"), a leading health ingredient manufacturer from Finland, today announces that it has entered a multi-year sales agreement. The sales agreement is with a Finnish customer to supply a specialty protein and fiber plant extract with excellent nutritional values and versatile product applications for the global nutraceutical market.

2021-11-16
Regulatory

The Board and CEO of Eevia Health Plc now present the Interim Report for the third quarter of 2021, covering the period 1 July through 30 September 2021. The complete report with tables is attached to this release as a pdf-file. It is also available on the company website at www.eeviahealth.com

2021-11-12
Regulatory

Notice is given to the shareholders of Eevia Health Abp (Plc) to the Extraordinary General Meeting to be held on 9th of December, 2021 at 1.00 pm at the main office of Eevia Health Plc in Koulukatu 14, Seinäjoki, Finland. The reception of persons who have registered for the meeting and the distribution of voting tickets will commence at 12.30 pm.

2021-11-11
Regulatory

This is a correction to press release published 10 November, 2021 where the press release lacked a reference to the EU's Market Abuse Regulation (MAR).

The Board of Directors of Eevia Health Plc (publ) ("Eevia" or the "Company") has resolved, subject to the approval by shareholders at an Extraordinary General Meeting (the "EGM"), on a directed new issue of 2,061,856 shares at a subscription price of SEK 9.70 per share (the "Directed Share Issue"), which is expected to raise proceeds to the Company of SEK 20 million before issue costs. The proceeds will primarily be used for investments in increased capacity to better be able to meet current and future demand.

1
2